Costs and Clinical Outcomes of Noninvasive Fetal RhD Typing for Targeted Prophylaxis
- 1 September 2013
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Obstetrics & Gynecology
- Vol. 122 (3), 579-585
- https://doi.org/10.1097/aog.0b013e31829f8814
Abstract
To examine the cost and clinical outcomes of noninvasive RhD typing with cell-free fetal DNA to selectively deliver antenatal and postnatal prophylaxis with anti-D immune globulin for prevention of alloimmunization in RhD-negative women. We developed a decision tree to compare the costs and clinical outcomes of three strategies in an RhD-negative nonalloimmunized population as follows: 1) routine antenatal anti-D immune globulin prophylaxis and postpartum prophylaxis guided by cord blood typing (the current approach in most of the United States); 2) noninvasive fetal RhD typing with prophylaxis guided by test results; and 3) no screening or prophylaxis. Costs were estimated for testing and treatment algorithms using hospital billing records and information from the manufacturer of the fetal RhD genotyping test. Probability estimates were derived from published literature. The decision tree and sensitivity analyses were constructed and performed with Microsoft Excel. We estimated the cost of the current approach to prevention of alloimmunization to be $351 per pregnancy, and we estimated the cost of noninvasive determination of fetal RhD status to be $682. Assuming essentially perfect test performance, threshold analysis found the cost must decrease to $119 to break even. The gap widened in favor of routine prophylaxis in most other circumstances (increased false-negative test rate and decreasing prevalence of RhD negativity). Unless the cost of noninvasive fetal RhD typing is reduced substantially, routine antenatal anti-D immune globulin prophylaxis with postpartum prophylaxis guided by cord blood typing is less costly than noninvasive determination of fetal RhD status.Keywords
This publication has 18 references indexed in Scilit:
- Noninvasive Single-Exon Fetal RHD Determination in a Routine Screening Program in Early PregnancyObstetrics & Gynecology, 2012
- Fetal RHD genotype detection from circulating cell‐free fetal DNA in maternal plasma in non‐sensitized RhD negative womenPrenatal Diagnosis, 2011
- A new fetal RHD genotyping test: Costs and benefits of mass testing to target antenatal anti-D prophylaxis in England and WalesBMC Pregnancy and Childbirth, 2011
- The safety of RhIG in the prevention of haemolytic disease of the newbornJournal of Obstetrics and Gynaecology, 2007
- ACOG Practice Bulletin No. 75: Management of AlloimmunizationObstetrics & Gynecology, 2006
- Obstetric Outcome in Women With Threatened Miscarriage in the First TrimesterObstetrics & Gynecology, 2006
- Ultrasound Assessment of First-Trimester BleedingObstetrics & Gynecology, 2005
- Clinical Outcomes after Hepatitis C Infection from Contaminated Anti-D Immune GlobulinThe New England Journal of Medicine, 1999
- Prenatal Diagnosis of Fetal RhD Status by Molecular Analysis of Maternal PlasmaThe New England Journal of Medicine, 1998
- Presence of fetal DNA in maternal plasma and serumThe Lancet, 1997